Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

Posted a reply to that seeking alpha fake

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Bescaredxx Member Profile
Followed By 2
Posts 134
Boards Moderated 0
Alias Born 11/21/16
160x600 placeholder
Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management "NetworkNewsWire" - 12/6/2017 8:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/4/2017 7:31:33 AM
Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 ... "GlobeNewswire Inc." - 12/3/2017 12:01:00 PM
Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES) "GlobeNewswire Inc." - 11/21/2017 9:00:00 AM
Innovation Drives Value for Leading Cannabis Biotechs "NetworkNewsWire" - 11/15/2017 8:45:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/14/2017 8:03:15 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/14/2017 7:31:54 AM
Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights "GlobeNewswire Inc." - 11/14/2017 7:30:00 AM
Biotech M&A Momentum Attractive for Cannabinoid R&D Space "NetworkNewsWire" - 11/7/2017 8:45:00 AM
Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences "GlobeNewswire Inc." - 11/7/2017 7:30:00 AM
Economic Impact of Biosynthesis on the Cannabis Industry "NetworkNewsWire" - 10/31/2017 8:45:00 AM
Innovative Biotechnology Companies are Transforming Cannabis-based Medical Products "NetworkNewsWire" - 10/26/2017 8:45:00 AM
How Biosynthesis is Revolutionizing Cannabinoid Pharmaceuticals "NetworkNewsWire" - 10/24/2017 8:45:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/23/2017 7:26:26 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/11/2017 8:01:50 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:09:06 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:08:13 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:07:22 PM
Cannabinoid Biosynthesis Poised as Potential Game-Changer in Drug Development "NetworkNewsWire" - 9/28/2017 8:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/28/2017 7:02:33 AM
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile... "GlobeNewswire Inc." - 9/28/2017 6:30:00 AM
Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development "NetworkNewsWire" - 9/26/2017 8:45:00 AM
Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects "NetworkNewsWire" - 9/19/2017 8:45:00 AM
Biosynthesis Technology Could Transform Cannabinoid Production "NetworkNewsWire" - 9/13/2017 8:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/11/2017 5:02:12 PM
Bescaredxx   Thursday, 10/05/17 09:31:55 PM
Re: None
Post # of 1012 
Posted a reply to that seeking alpha fake news today! They would not publish it so here it is!

Ok so before you post any article you might want to do a little bit more DD. Try contacting the company see what has progressed.

Lets start with this, 5 phase 3 trials. Well each one has about 33% chance of being FDA approved. So that means at least one or even two make it.

1) Do they have the cash to get there? Well yes they do!

2) Do they have good management with FDA experience? Yes they do!

3) Do they have a broad pipeline meeting all time frames so far? Yes they do.

4) Is it possible to do a placebo trial on patients unaware they are even receiving treatment? Well thats pretty pointless. (FXS)

5) Do you know how much the phase 3 trials for FXS cost? Ok ill tell you about 5-10 million total. Best and cheapest runway for success!

6) How about there are no known treatments for spectrum disorders.

7) How about patented past 2030 with orphan drug designation giving almost a decade of exclusive marketing!

Ok now lets talk about O/A or osteoarthritis.

Met the most important secondary endpoints! Worked in men and not women. Restructure this with the FDA for phase 3 probably gonna have a solid update for this in December.

O/A largest market but also costly phase3 ($20+ million 300+ patients)

How about Zyn001? Well the only pro THC derived transdermal synthetic thats patent protected with all the same as above minus the results.

I tell you what my bet is here! any placebo test is an open and shut case

i believe that passing on this opportunity to buy the stock will be a large mistake people will look back and say wow i could have bought that for how much?! Its already traded at $25 before any results, has a low float enough cash till 2019 and is in the largest market space with the highest potential growth in the next 5 years!

Sorry for the rant here but i have alot to say and this article was pitiful! Longs will be winners here mark my words!

Thanks for the support of all my friends who held on through this rough ride, we should be rewarded handsomely!


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist